No  treatment or prevention methods are established, but patients with upper-extremity PTS may wear a compression sleeve for persistent symptoms. Epidemiology
PTS can affect 23 to 60% of patients in the two years following DVT of the leg. Of those, 10% may go on to develop severe PTS, involving venous ulcers. Society and culture
Treatment of PTS adds significantly to the cost of treating DVT. The annual health care cost of PTS in the United States has been estimated at $200 million, with costs over $3800 per patient in the first year alone, and increasing with disease severity. PTS also causes lost work productivity: people with severe PTS and venous ulcers lose up to 2 work days per year. Research directions
The field of PTS still holds many unanswered questions that are important targets for more research. Those include

Fully defining the pathophysiology of PTS, including the role of inflammation and residual thrombus after completion of an appropriate duration of anticoagulant therapy
Developing a PTS risk prediction model
Role of thrombolytic ("clot-busting") drugs in PTS prevention
Defining the true efficacy of elastic compression stockings for PTS prevention (and if effective, elucidating the minimum compression strength necessary and the optimal timing and duration of compression therapy)
Whether PTS prevention methods are necessary for patients with asymptomatic or distal DVT
Additional treatment options for PTS with demonstrated safety and efficacy (compression and pharmacologic therapies)

References


== External links ==
Severe hypotonia can lead to fatal infant respiratory distress syndrome or apnea within the first days or weeks of life. Conversely, in mild cases, subjects live relatively normal lives with some developmental delays and mild to moderate intellectual disability. References
External links

Acrocallosal syndrome, Schinzel type at NIHs Office of Rare Diseases